{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:52:12Z","timestamp":1790963532346,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>This review focuses on the feasibility of combining Bruton\u2019s tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R\/R) mantle cell lymphoma (MCL). Potential scenarios for combination treatment with these agents are presented.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>BTKis and CAR T-cell therapy have revolutionized the treatment paradigm for R\/R MCL. Ibrutinib, acalabrutinib, and zanubrutinib are covalent irreversible BTKis approved for R\/R MCL. Brexucabtagene autoleucel was the first CAR T-cell therapy approved for R\/R MCL based on findings from the ZUMA-2 trial. There is evidence to suggest that combination treatment with BTKis and CAR T-cell therapy may improve CAR T-cell efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>As BTKis and CAR T-cell therapy become mainstays in R\/R MCL therapy, combination treatment strategies should be evaluated for their potential benefit in R\/R MCL.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11912-022-01286-0","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T13:04:22Z","timestamp":1653138262000},"page":"1299-1311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma\u2014Finding a Dancing Partner"],"prefix":"10.1007","volume":"24","author":[{"given":"Javier L.","family":"Munoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"1286_CR1","doi-asserted-by":"crossref","unstructured":"Jain P, Wang ML. Mantle cell lymphoma\u2014a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638\u201356.","DOI":"10.1002\/ajh.26523"},{"issue":"2","key":"1286_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312\u201332.","journal-title":"Leukemia."},{"issue":"6","key":"1286_CR3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739\u201345.","journal-title":"Blood."},{"issue":"8","key":"1286_CR4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","volume":"32","author":"S Rule","year":"2018","unstructured":"Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799\u2013803.","journal-title":"Leukemia."},{"issue":"1","key":"1286_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","volume":"14","author":"D Gu","year":"2021","unstructured":"Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"1286_CR6","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","volume":"2","author":"SM Jaglowski","year":"2018","unstructured":"Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018;2(15):2012\u20139.","journal-title":"Blood Adv"},{"issue":"15","key":"1286_CR7","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539\u201349.","journal-title":"Blood."},{"key":"1286_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"1286_CR9","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton's tyrosine kinase. J Med Chem. 2019;62(17):7923\u201340.","journal-title":"J Med Chem"},{"issue":"10121","key":"1286_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659\u201367.","journal-title":"Lancet."},{"key":"1286_CR11","doi-asserted-by":"publisher","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al.\u00a0Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022. https:\/\/doi.org\/10.1182\/blood.2021014162.","DOI":"10.1182\/blood.2021014162"},{"issue":"14","key":"1286_CR12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"\u2022\u2022 Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342 This was the pivotal clinical trial that led to the US FDA approval of brexucabtagene autoleucel for patients with R\/R MCL.","journal-title":"N Engl J Med"},{"issue":"4","key":"1286_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578\u201387.","journal-title":"Br J Haematol"},{"key":"1286_CR14","doi-asserted-by":"publisher","first-page":"591577","DOI":"10.3389\/fonc.2020.591577","volume":"10","author":"L Ondrisova","year":"2020","unstructured":"Ondrisova L, Mraz M. Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies. Front Oncol. 2020;10:591577.","journal-title":"Front Oncol"},{"issue":"6","key":"1286_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MOH.0000000000000548","volume":"26","author":"X Li","year":"2019","unstructured":"Li X, Chen W. Mechanisms of failure of chimeric antigen receptor T-cell therapy. Curr Opin Hematol. 2019;26(6):427\u201333.","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"1286_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ijc.33212","volume":"148","author":"F Fan","year":"2021","unstructured":"Fan F, Yoo HJ, Stock S, Wang L, Liu Y, Schubert ML, et al. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Int J Cancer. 2021;148(2):419\u201328.","journal-title":"Int J Cancer"},{"issue":"9","key":"1286_CR17","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117\u201327.","journal-title":"Blood."},{"issue":"7","key":"1286_CR18","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/cas.14915","volume":"112","author":"M Liu","year":"2021","unstructured":"Liu M, Deng H, Mu J, Li Q, Pu Y, Jiang Y, et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Cancer Sci. 2021;112(7):2642\u201351.","journal-title":"Cancer Sci"},{"issue":"19","key":"1286_CR19","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, et al. Feasibility and efficacy of CD19-targeted CAR T-cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650\u201360.","journal-title":"Blood."},{"issue":"22","key":"1286_CR20","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1182\/bloodadvances.2020003391","volume":"4","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Maus MV. C(h)AR-ting a new course in incurable lymphomas: CAR T-cells for mantle cell and follicular lymphomas. Blood Adv. 2020;4(22):5858\u201362.","journal-title":"Blood Adv"},{"issue":"4","key":"1286_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","volume":"43","author":"JS Qin","year":"2020","unstructured":"Qin JS, Johnstone TG, Baturevych A, Hause RJ, Ragan SP, Clouser CR, et al. Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib. J Immunother. 2020;43(4):107\u201320.","journal-title":"J Immunother"},{"issue":"1","key":"1286_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","volume":"13","author":"W Hanel","year":"2020","unstructured":"Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79.","journal-title":"J Hematol Oncol"},{"issue":"10020","key":"1286_CR23","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770\u20138.","journal-title":"Lancet."},{"key":"1286_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2020-134824","volume":"136","author":"M Wang","year":"2020","unstructured":"Wang M, Rule S, PL ZI, Goy AH, Casasnovas R-O, Smith SD, et al. Acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2020;136:38\u20139.","journal-title":"Blood."},{"issue":"10277","key":"1286_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901.","journal-title":"Lancet."},{"key":"1286_CR26","doi-asserted-by":"crossref","unstructured":"Wang ML, Shah N, Alencar A, Gerson JN, Patel MR, Fakhri B, et al. Pirtobrutinib, a highly selective, non-covalent, (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1\/2 BRUIN study.\u00a0Blood. 2021;138(Suppl 1):381.","DOI":"10.1182\/blood-2021-149138"},{"key":"1286_CR27","first-page":"9583257","volume":"2017","author":"D Mannina","year":"2017","unstructured":"Mannina D, Loteta B. Ibrutinib treatment of mantle cell lymphoma relapsing at central nervous system: a case report and literature review. Case Rep Hematol. 2017;2017:9583257.","journal-title":"Case Rep Hematol"},{"issue":"14","key":"1286_CR28","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","volume":"126","author":"S Bernard","year":"2015","unstructured":"Bernard S, Goldwirt L, Amorim S, Brice P, Briere J, de Kerviler E, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126(14):1695\u20138.","journal-title":"Blood."},{"key":"1286_CR29","doi-asserted-by":"publisher","first-page":"760405","DOI":"10.3389\/fonc.2021.760405","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Zhuang Z, Wang W, Wei C, Zhao D, et al. Preliminary evaluation of zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: a 13-case series. Front Oncol. 2021;11:760405.","journal-title":"Front Oncol"},{"key":"1286_CR30","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u0148an","year":"2021","unstructured":"Estupi\u0148an HY, Berglof A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.","journal-title":"Front Cell Dev Biol"},{"key":"1286_CR31","doi-asserted-by":"publisher","first-page":"668162","DOI":"10.3389\/fonc.2021.668162","volume":"11","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Wierda WG. Acalabrutinib: a selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol. 2021;11:668162.","journal-title":"Front Oncol"},{"issue":"18","key":"1286_CR32","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood.2020006449","volume":"136","author":"J Trotman","year":"2020","unstructured":"Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, et al. Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027\u201337.","journal-title":"Blood."},{"issue":"5","key":"1286_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15(5):835\u201347.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1286_CR34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/leu.2014.247","volume":"29","author":"S Kamel","year":"2015","unstructured":"Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783\u20137.","journal-title":"Leukemia."},{"issue":"31","key":"1286_CR35","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.21.00693","volume":"39","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study. J Clin Oncol. 2021;39(31):3453\u201362.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1286_CR36","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1286_CR37","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.14870","volume":"179","author":"S Rule","year":"2017","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430\u20138.","journal-title":"Br J Haematol"},{"issue":"3","key":"1286_CR38","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.21037\/apm.2019.08.05","volume":"9","author":"T McFarlane","year":"2020","unstructured":"McFarlane T, Rehman N, Wang K, Lee J, Carter C. Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. Ann Palliat Med. 2020;9(3):1296\u2013306.","journal-title":"Ann Palliat Med"},{"issue":"18","key":"1286_CR39","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038\u201350.","journal-title":"Blood."},{"issue":"6","key":"1286_CR40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833\u201343 e5.","journal-title":"Cancer Cell"},{"issue":"17","key":"1286_CR41","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"D Ghez","year":"2018","unstructured":"Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955\u20139.","journal-title":"Blood."},{"key":"1286_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2019-125488","volume":"134","author":"SM Handunetti","year":"2019","unstructured":"Handunetti SM, Sang Tang CP, Nguyen T, Zhou X, Thompson E, Sun H, et al. BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib. Blood. 2019;134:170.","journal-title":"Blood."},{"key":"1286_CR43","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2019-127674","volume":"134","author":"JA Woyach","year":"2019","unstructured":"Woyach JA, Huang Y, Rogers K, Bhat SA, Grever MR, Lozanski A, et al. Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations. Blood. 2019;134:504.","journal-title":"Blood."},{"issue":"1","key":"1286_CR44","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021;12(1):2877.","journal-title":"Nat Commun"},{"key":"1286_CR45","doi-asserted-by":"publisher","first-page":"689472","DOI":"10.3389\/fimmu.2021.689472","volume":"12","author":"CIE Smith","year":"2021","unstructured":"Smith CIE, Burger JA. Resistance mutations to BTK inhibitors originate from the NF-kappaB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway. Front Immunol. 2021;12:689472.","journal-title":"Front Immunol"},{"issue":"2","key":"1286_CR46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41419-017-0157-6","volume":"9","author":"H Rauert-Wunderlich","year":"2018","unstructured":"Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A. CD40L mediated alternative NFkappaB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death Dis. 2018;9(2):86.","journal-title":"Cell Death Dis"},{"issue":"S1","key":"1286_CR47","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3\u20139.","journal-title":"Am J Hematol"},{"key":"1286_CR48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fonc.2020.00849","volume":"10","author":"C Vitale","year":"2020","unstructured":"Vitale C, Strati P. CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10:849.","journal-title":"Front Oncol"},{"issue":"12","key":"1286_CR49","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T-cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25(12):2305\u201321.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1286_CR50","unstructured":"\u2022\u2022 Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, et al. Brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma: real world experience from the US Lymphoma CAR T Consortium. Blood. 2021;138. This real-world study showed that brexucabtagene autoleucel can be prescribed as standard of care with similar efficacy and toxicity as compared with the pivotal clinical trial (ZUMA-2) experience."},{"key":"1286_CR51","first-page":"20","volume":"136","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy AH, Locke FL, Jacobson CA, Hill BT, et al. One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma. Blood. 2020;136:20\u20132.","journal-title":"Blood."},{"key":"1286_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-136158","volume":"136","author":"ML Palomba","year":"2020","unstructured":"Palomba ML, Gordon LI, Siddiqi T, Abramson JS, Kamdar M, Lunning MA, et al. Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in Transcend NHL 001. Blood. 2020;136:10\u20131.","journal-title":"Blood."},{"key":"1286_CR53","doi-asserted-by":"crossref","unstructured":"Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, et al. Brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma: real world experience from the US Lymphoma CAR T Consortium.\u00a0Blood. 2021;138(Suppl 1):744.","DOI":"10.1182\/blood-2021-147563"},{"key":"1286_CR54","doi-asserted-by":"crossref","unstructured":"Romancik JT, Goyal S, Gerson JN, Ballard HJ, Sawalha Y, Bond DA, et al. Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel.\u00a0Blood. 2021;138(Suppl 1):1756.","DOI":"10.1182\/blood-2021-153277"},{"issue":"Suppl 1","key":"1286_CR55","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1182\/blood-2021-153277","volume":"138","author":"JT Romancik","year":"2021","unstructured":"Romancik JT, Goyal S, Gerson JN, Ballard HJ, Sawalha Y, Bond DA, et al. Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel. Blood. 2021;138(Suppl 1):1756.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1286_CR56","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1182\/blood-2021-148626","volume":"138","author":"G Herbaux","year":"2021","unstructured":"Herbaux G, Bret C, Di Blasi R, Bachy E, Beauvais D, Gat E, et al. Kte-X19 in relapsed or refractory mantle-cell lymphoma, a \"real-life\" study from the Descar-T Registry and Lysa Group. Blood. 2021;138(Suppl 1):743.","journal-title":"Blood."},{"issue":"26","key":"1286_CR57","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T-cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010\u201320.","journal-title":"J Clin Oncol"},{"key":"1286_CR58","doi-asserted-by":"crossref","unstructured":"Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL.\u00a0Blood. 2022;139(12):1794\u20131806.","DOI":"10.1182\/blood.2021011895"},{"key":"1286_CR59","unstructured":"ClinicalTrials.gov. Study to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed\/refractory mantle cell lymphoma (ZUMA-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02601313. Accessed November 3, 2021."},{"issue":"Suppl 1","key":"1286_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-136831","volume":"136","author":"M Wang","year":"2020","unstructured":"\u2022 Wang M, Rossi JM, Munoz J, Goy AH, Locke FL, Reagan PM, et al. Pharmacological profile and clinical outcomes of KTE-X19 by prior Bruton tyrosine kinase inhibitor (BTKi) exposure or mantle cell lymphoma (MCL) morphology in patients with relapsed\/refractory (R\/R) MCL in the ZUMA-2 trial. Blood. 2020;136(Suppl 1):29 This analysis showed that there may be a difference in outcomes depending on which BTKi is chosen as bridging therapy prior to the administration of brexucabtagene autoleucel (KTE-X19).","journal-title":"Blood"},{"key":"1286_CR61","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1182\/blood-2021-146941","volume":"138","author":"I Scarfo","year":"2021","unstructured":"Scarfo I, Gallagher KME, Leick MB, Kann NC, Budka J, Sowirajan B, et al. Effects of prior exposure to Tec kinase (BTK\/ITK) inhibitors on Kte-X19 products. Blood. 2021;138:3849.","journal-title":"Blood."},{"issue":"4","key":"1286_CR62","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 4","key":"1286_CR63","doi-asserted-by":"publisher","first-page":"e000746","DOI":"10.1136\/esmoopen-2020-000746","volume":"4","author":"L Yanez","year":"2020","unstructured":"Yanez L, Alarcon A, Sanchez-Escamilla M, Perales MA. How I treat adverse effects of CAR-T-cell therapy. ESMO Open. 2020;4(Suppl 4):e000746.","journal-title":"ESMO Open"},{"issue":"3","key":"1286_CR64","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T-cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"1286_CR65","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/blood-2021-150431","volume":"138","author":"JH Park","year":"2021","unstructured":"Park JH, Sauter CS, Palomba ML, Shah GL, Dahi PB, Lin RJ, et al. A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T-cell therapy for relapsed or refractory lymphoma. Blood. 2021;138(Suppl 1):96.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1286_CR66","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood-2021-150592","volume":"138","author":"SW Wong","year":"2021","unstructured":"Wong SW, Richard S, Lin Y, Madduri D, Jackson CC, Zudaire E, et al. Anakinra targeting cytokine release syndrome associated with chimeric antigen receptor T-cell therapies. Blood. 2021;138(Suppl 1):2812.","journal-title":"Blood."},{"key":"1286_CR67","doi-asserted-by":"crossref","unstructured":"Frigault MJ, Gallagher KME, Wehrli M, Valles B, Casey K, Lindell K, et al. A phase II trial of anakinra for prevention of CAR-T-cell mediated neurotoxicity. Blood.\u00a02021;138(Suppl 1):2814.","DOI":"10.1182\/blood-2021-146927"},{"issue":"10","key":"1286_CR68","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"issue":"5","key":"1286_CR69","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3324\/haematol.2020.267914","volume":"106","author":"FS Peters","year":"2021","unstructured":"Peters FS, Strefford JC, Eldering E, Kater AP. T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica. 2021;106(5):1234\u201343.","journal-title":"Haematologica."},{"issue":"Suppl 1","key":"1286_CR70","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/blood-2021-151073","volume":"138","author":"MM Adada","year":"2021","unstructured":"Adada MM, Sakemura R, Cox MJ, Manriquez-Roman C, Siegler EL, Tapper E, et al. Favorable modulation of chimeric antigen receptor T-cells safety and efficacy by the non-covalent BTK inhibitor vecabrutinib. Blood. 2021;138(Suppl 1):906.","journal-title":"Blood."},{"key":"1286_CR71","unstructured":"ClinicalTrials.gov. Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (TARMAC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04234061. Accessed October 27, 2021."},{"key":"1286_CR72","unstructured":"ClinicalTrials.gov. A Phase 2 Study to Evaluate CD19-Specific Chimeric Antigen Receptor(CAR)-T-Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04484012. Accessed December 20, 2021."},{"issue":"12","key":"1286_CR73","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11864-021-00907-3","volume":"22","author":"JT Romancik","year":"2021","unstructured":"Romancik JT, Cohen JB. Sequencing of novel therapies for mantle cell lymphoma. Curr Treat Options in Oncol. 2021;22(12):118.","journal-title":"Curr Treat Options in Oncol"},{"issue":"2","key":"1286_CR74","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68\u201371.","journal-title":"Haematologica."},{"issue":"1","key":"1286_CR75","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13045-021-01188-x","volume":"14","author":"M Wang","year":"2021","unstructured":"Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, et al. Concurrent ibrutinib plus venetoclax in relapsed\/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021;14(1):179.","journal-title":"J Hematol Oncol"},{"key":"1286_CR76","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","volume":"97","author":"IG Solman","year":"2020","unstructured":"Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97:106432.","journal-title":"Leuk Res"},{"issue":"7","key":"1286_CR77","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/imcb.12254","volume":"97","author":"AD McLellan","year":"2019","unstructured":"McLellan AD, Ali Hosseini Rad SM. Chimeric antigen receptor T-cell persistence and memory cell formation. Immunol Cell Biol. 2019;97(7):664\u201374.","journal-title":"Immunol Cell Biol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01286-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01286-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01286-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T21:22:21Z","timestamp":1675632141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01286-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01286-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"21 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P. Jain reports other support from Eli Lilly. Y. Wang reports other support from Incyte, InnoCare, Loxo Oncology, Novartis, Genentech, Eli Lilly, Kite, and TG therapeutics, all outside the submitted work. M. Wang reports grants from Molecular Templates, personal fees from Anticancer Association, Bayer Healthcare, CStone, Chinese Medical Association, Clinical Care Options, DTRM Biopharma (Cayman) Limited, Dava Oncology, Epizyme, Genentech, Hebei Cancer Prevention Federation, CAHON, Imbruvica, Imedex, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals. OMI, Physicians Education Resources (PER), Scripps, The First Affiliated Hospital of Zhejiang University; grants and personal fees from Acerta Pharma, BeiGene, AstraZeneca, Pharmacyclics, BioInvent, Celgene, Innocare, Janssen, Juno, Kite Pharma, Loxo Oncology, and Oncternal, VelosBio, all outside the submitted work. J.L. Munoz reports consulting fees from Pharmacyclics\/AbbVie, Bayer, Gilead\/Kite Pharma, Pfizer, Janssen, Juno\/Celgene, Bristol Myers Squibb, Kyowa, Alexion, Fosun Kite, Innovent Bio, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, BeiGene, Servier Laboratories, Novartis, MorphoSys\/Incyte, and Eli Lilly; research funding from Bayer, Gilead\/Kite Pharma, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, and Millennium; honoraria from Targeted Oncology, OncView, Curio, Kyowa, Physicians\u2019 Education Resource, and Seattle Genetics; and participation in speaker bureaus sponsored by Gilead\/Kite Pharma, Kyowa, Bayer, Pharmacyclics\/Janssen, Seattle Genetics, Acrotech\/Aurobindo, BeiGene, Verastem Oncology, AstraZeneca, Celgene\/Bristol Myers Squibb, and Genentech\/Roche, all outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}